Davita Inc vs Elastic NV — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Elastic NV trades at $95.26 (market cap $10.00B). The key difference: Davita Inc and Elastic NV are close in size by market cap, and Elastic NV is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Elastic NV for 10 Days on average.
| DVA | ESTC | |
|---|---|---|
Market Cap | $11.29B | $10.00B |
Volume | 582,204 | 1,610,337 |
Sector | Health | Technology |
52-Week High | $240.96 | $99.91 |
52-Week Low | $103.87 | $43.30 |
Typical Hold Time | 113 Days | 10 Days |
Enterprise Value | $24.01B | $9.14B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Elastic (ESTC) trades at $93.10, down 1.59% today but maintains strong technical momentum with a bullish moving average signal. The company shows robust revenue growth with Q2 2026 EPS beating expectations at $0.70 versus $0.584, and analyst consensus remains strongly positive with 22 buy ratings and no sell recommendations. Recent product launches including AI-powered metrics and serverless vector database enhancements demonstrate ongoing innovation.
The outlook remains favorable with projected revenue growth to $1.8B in 2026 and net income turning positive to $376M. Key risks include high valuation multiples and competitive pressures in the enterprise software space. The consensus price target of $79.50 suggests potential downside from current levels despite strong fundamentals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →